Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Phico Therapeutics awarded £13.2m by CARB-X accelerator to fight anti-bacterial resistance
23 April 2021
Cambridge Angels
Phico Therapeutics awarded £13.2m by CARB-X accelerator to fight anti-bacterial resistance
Cambridge Angels
23 April 2021

Phico Therapeutics awarded £13.2m by CARB-X accelerator to fight anti-bacterial resistance

Cambridge Angels
23 April 2021

Source:https://www.businessweekly.co.uk/tech-trail/tech-profiles/near-death-experience-breathes-life-small-molecule-startup

Newer PostHealx hires ex-Dyson and GCHQ ace as VP of AI
Older PostNear-death experience breathes life into small molecule startup
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net